olfactory receptor family 9 subfamily I member 2 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR9I2P profile across patient tissues and cancer cell-line models. OR9I2P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OR9I2P is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, OR9I2P RNA expression shows 5,787 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight MESO, KIRC, and UCEC as cancer lineages where OR9I2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR9I2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR9I2P survival associations across molecular data types. OR9I2P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR9I2P RNA expression–survival associations across cancer types. High OR9I2P expression shows unfavorable associations in MESO, BRCA, PCPG, ACC and PAAD, but favorable associations in STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OR9I2P RNA expression.
This table summarizes OR9I2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR9I2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR9I2P shows higher tumor expression in KIRC and COAD. The KIRC box plot shows higher OR9I2P RNA expression in tumor versus normal tissue (log2 FC = +0.071, t-test p < 0.001).
This table shows molecular features associated with OR9I2P in patient tissues and cancer cell lines. In patient samples, OR9I2P shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
